ACADIA Pharmaceuticals Inc. - notizie pubblicate 221 - letture 4.822
ACADIA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference
San diego-(business wire)-aug. 7, 2024- acadia pharmaceuticals inc. (nasdaq: acad) today announced that it will participate in a fireside chat at the canaccord genuity 44th annual ...
ACADIA PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)
10-q united states securities and exchange commission washington, d.c. 20549 form 10-q ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 1934 f ...
ACADIA PHARMACEUTICALS INC.
Acadia 2Q24 Earnings Presentation
Second quarter 2024 earnings call august 6, 2024 call agenda welcome al kildani | senior vice president, investor relations and corporate communications ceo opening remarks steve d ...
ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview
- second quarter total net product sales of $242.0 million, up 46% year-over-year san diego-(business wire)-aug. 6, 2024- acadia pharmaceuticals inc. (nasdaq: acad) today announced ...
ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview Form 8 K
Acadia pharmaceuticals reports second quarter 2024 financial results and operating overview - second quarter total net product sales of $242.0 million, up 46% year-over-year san di ...
ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
Company to host conference call and webcast on tuesday, august 6, 2024, at 4:30 p.m. eastern time san diego-(business wire)-jul. 24, 2024- acadia pharmaceuticals inc. (nasdaq: acad ...
ACADIA PHARMACEUTICALS INC.
Clinical Data from Open Label Extension LILAC 1™ and LILAC 2™ Studies Evaluating Long Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
- continued improvements in rsbq and cgi-i scores seen with long-term daybue treatment in phase 3 lavender™ and lilac studies - daybue safety profile was consistent with findings ...
ACADIA PHARMACEUTICALS INC.
Acadia Corporate Presentation
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer acadia pharmaceuticals inc. published ...
ACADIA PHARMACEUTICALS INC.
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
San diego-(business wire)-jun. 18, 2024- acadia pharmaceuticals, inc. (nasdaq: acad) today announced that interim data from the open-label real-world lotus™ study will be present ...
ACADIA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ACADIA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ACADIA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ACADIA PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ACADIA PHARMACEUTICALS INC.
Post-effective Amendment to Registration Statement for Employee Benefit Plan - Form S-8 POS
S-8 pos as filed with the securities and exchange commission on may 29, 2024 registration no. 333-168667 registration no. 333-190400 registration no. 333-207971 registration no. 33 ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti